Literature DB >> 22766194

The human CD10 lacking an N-glycan at Asn(628) is deficient in surface expression and neutral endopeptidase activity.

Ban Sato1, Yohko U Katagiri, Kazutoshi Iijima, Hiroyuki Yamada, Satsuki Ito, Nana Kawasaki, Hajime Okita, Junichiro Fujimoto, Nobutaka Kiyokawa.   

Abstract

BACKGROUND: CD10, also known as neprilysin or enkephalinase exhibiting neutral endopeptidase (NEP) activity, is expressed by B-lineage hematopoietic cells as well as a variety of cells from normal tissues. It cleaves peptides such as cytokines to act for terminating inflammatory responses. Although CD10 molecules of the human pre-B-cell line NALM-6 have 6 consensus N-glycosylation sites, three of them are known to be N-glycosylated by X-ray crystallography.
METHODS: In order to investigate the role of N-glycans in the full expression of NEP activity, we modified N-glycans by treatment of NALM6 cells with various glycosidases or alter each of the consensus N-glycosylation sites by generating site-directed mutagenesis and compared the NEP activities of the sugar-altered CD10 with those of intact CD10.
RESULTS: CD10 of the human B-cell line NALM-6 was dominantly localized in raft microdomains and heterogeneously N-glycosylated. Although neither desialylation nor further degalactosylation caused defective NEP activity, removal of only a small part of N-glycans by treatment with glycopeptidase F under non-denaturing conditions decreased NEP activity completely. All of the three consensus sites of CD10 in HEK293 cells introduced with wild type-CD10 were confirmed to be N-glycosylated. Surface expression of N-glycan at Asn(628)-deleted CD10 by HEK293 cells was greatly decreased as well as it lost entire NEP activities.
CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression. GENERAL SIGNIFICANCE: Quality control system does not allow dysfunctional ecto-type proteases to express on plasma membrane.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766194     DOI: 10.1016/j.bbagen.2012.06.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Cancer stem cell marker glycosylation: Nature, function and significance.

Authors:  Brody W Mallard; Joe Tiralongo
Journal:  Glycoconj J       Date:  2017-06-17       Impact factor: 2.916

Review 2.  Early Stage Glycosylation Biomarkers in Alzheimer's Disease.

Authors:  Patricia Regan; Paula L McClean; Thomas Smyth; Margaret Doherty
Journal:  Medicines (Basel)       Date:  2019-09-03

3.  GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness.

Authors:  Kai Jiang; Wei Li; Qinle Zhang; Guoquan Yan; Kun Guo; Shu Zhang; Yinkun Liu
Journal:  Oncotarget       Date:  2016-04-26

4.  Endoplasmic Reticulum Associated Degradation of Spinocerebellar Ataxia-Related CD10 Cysteine Mutant.

Authors:  Mai Kanuka; Fuka Ouchi; Nagisa Kato; Riko Katsuki; Saori Ito; Kohta Miura; Masaki Hikida; Taku Tamura
Journal:  Int J Mol Sci       Date:  2020-06-14       Impact factor: 5.923

Review 5.  The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer's Disease.

Authors:  Vidyasagar Naik Bukke; Rosanna Villani; Moola Archana; Agata Wawrzyniak; Krzysztof Balawender; Stanislaw Orkisz; Luca Ferraro; Gaetano Serviddio; Tommaso Cassano
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.